LOS ANGELES, March 09, 2017 -- Motorcar Parts of America, Inc. (Nasdaq:MPAA) today announced it is scheduled to make a presentation on Tuesday, March 14, 2017 at 10:30 a.m. Pacific time at the 29th Annual Roth Conference in Laguna Niguel at The Ritz Carlton Hotel.
Selwyn Joffe, chairman, president and chief executive officer will discuss the company’s business and industry trends in a fireside chat format. A live audio webcast of the discussion will be available through the link www.motorcarparts.com and archived for a period of 30 days.
An updated PowerPoint presentation will be available on Monday, March 13 via the company’s website address noted above. A newly created educational video on the company’s “Core Exchange Program” will be available via its website on Monday as well. The video complements management’s commitment and focus on providing investors with innovative tools to better understand the dynamics of its business.
About Motorcar Parts of America
Motorcar Parts of America is a remanufacturer, manufacturer and distributor of automotive aftermarket parts -- including alternators, starters, wheel hub assembly products, brake master cylinders, brake power boosters and turbochargers utilized in imported and domestic passenger vehicles, light trucks and heavy duty applications. Motorcar Parts of America’s products are sold to automotive retail outlets and the professional repair market throughout the United States and Canada, with facilities located in California, Mexico, Malaysia and China, and administrative offices located in California, Tennessee, Virginia, Mexico, Singapore, Malaysia and Toronto. Additional information is available at www.motorcarparts.com.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements. The statements contained in this press release that are not historical facts are forward-looking statements based on the company’s current expectations and beliefs concerning future developments and their potential effects on the company. These forward-looking statements involve significant risks and uncertainties (some of which are beyond the control of the company) and are subject to change based upon various factors. Reference is also made to the Risk Factors set forth in the company’s Form 10-K Annual Report filed with the Securities and Exchange Commission (SEC) in June 2016 and in its Forms 10-Q filed with the SEC for additional risks and uncertainties facing the company. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.
CONTACT: Gary S. Maier Maier & Company, Inc. (310) 471-1288


Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 



